Cargando…
A phase I study of irinotecan and pegylated liposomal doxorubicin in recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study)
PURPOSE: A phase I clinical study was conducted to determine the maximum tolerated dose (MTD) and the recommended dose (RD) of irinotecan hydrochloride (CPT-11) in CPT-11/pegylated liposomal doxorubicin (PLD) combination therapy, a novel treatment regimen for platinum- and taxane-resistant recurrent...
Autores principales: | Shoji, Tadahiro, Takatori, Eriko, Kaido, Yoshitaka, Omi, Hideo, Yokoyama, Yoshihito, Mizunuma, Hideki, Kaiho, Michiko, Otsuki, Takeo, Takano, Tadao, Yaegashi, Nobuo, Nishiyama, Hiroshi, Fujimori, Keiya, Sugiyama, Toru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4000409/ https://www.ncbi.nlm.nih.gov/pubmed/24585045 http://dx.doi.org/10.1007/s00280-014-2418-8 |
Ejemplares similares
-
A phase II study of irinotecan and pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study)
por: Shoji, Tadahiro, et al.
Publicado: (2017) -
A Phase II Study of S-1 plus Oxaliplatin for Patients with Recurrent Non-Squamous Cell Carcinoma of the Uterine Cervix (Tohoku Gynecologic Cancer Unit: TGCU206 Study)
por: Nagasawa, Takayuki, et al.
Publicado: (2023) -
Are platinum agents, paclitaxel and irinotecan effective for clear cell carcinoma of the ovary? DNA damage detected with γH2AX induced by anticancer agents
por: Takatori, Eriko, et al.
Publicado: (2012) -
Tohoku Medical Megabank Brain Magnetic Resonance Imaging Study: Rationale, Design, and Background
por: Taira, Makiko, et al.
Publicado: (2023) -
A case of ovarian adenosquamous carcinoma arising from endometrioid adenocarcinoma: a case report and systematic review
por: Shoji, Tadahiro, et al.
Publicado: (2016)